Law R.M. Law D.S. Maibach H.I.

Dermatologic drug reactions, contact dermatitis, and common skin conditions.

in: DiPiro J.T. Yee G.C. Posey L. Haines S.T. Nolin T.D. Ellingrod V. Pharmacotherapy: A Pathophysiologic Approach. 11th ed. McGraw Hill, 2020

Toxicodendron dermatitis: poison ivy, oak, and sumac.

Wilderness Environ Med. 2006; 17: 120-128Nadkarni A. Domeisen N. Hill D. Feldman S.R.

The most common dermatology diagnoses in the emergency department.

J Am Acad Dermatol. 2016; 75: 1261-1262Butt M. Flamm A. Marks J.G. Flamm A.

Poison ivy dermatitis treatment patterns and utilization: a retrospective claims-based analysis.

West J Emerg Med. 2022; 23: 481-488Gummin D.D. Mowry J.B. Beuhler M.C. Spyker D.A. Bronstein A.C. Rivers L.J. et al.

2020 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 38th annual report.

Clin Toxicol. 2021; 59: 1282-1501Liu B. Tai Y. Achanta S. Kaelberer M.M. Caceres A.I. Shao X. et al.

IL-33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy.

Proc Natl Acad Sci U S A. 2016; 113: E7572-E7579

Diagnosis and management of contact dermatitis.

Am Fam Physician. 2010; 82: 249-255Wakabayashi T. Hu D.L. Tagawa Y. Sekikawa K. Iwakura Y. Hanada K. et al.

IFN-gamma and TNF-alpha are involved in urushiol-induced contact hypersensitivity in mice.

Immunol Cell Biol. 2005; 83: 18-24Guin J.D. Gillis W.T. Beaman J.H.

Recognizing the Toxicodendrons (poison ivy, poison oak, and poison sumac).

J Am Acad Dermatol. 1981; 4: 99-114Kalish R.S. Wood J.A. LaPorte A.

Processing of urushiol (poison ivy) hapten by both endogenous and exogenous pathways for presentation to T cells in vitro.

J Clin Invest. 1994; 93: 2039-2047Slaughter R.J. Beasley M.G. Schep L.J.

Dermatitis due to Toxicodendron plants: a common occurrence during autumn.

N Z Med J. 2017; 130: 82-83

First Aid for the USMLE Step 1 2020.

13th edition. McGraw-Hill Education, 2020

Contact dermatitis.

in: Krinsky D.L. Ferreri S.P. Hemstreet B.A. Hume A.L. Newton G.D. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care. 20th ed. American Pharmacists Association, 2021: 715-729Grevelink S.A. Murrell D.F. Olsen E.A.

Effectiveness of various barrier preparations in preventing and/or ameliorating experimentally produced Toxicodendron dermatitis.

J Am Acad Dermatol. 1992; 27: 182-188

Lexicomp Online. Pramoxine.

Stibich A.S. Yagan M. Sharma V. Herndon B. Montgomery C.

Cost-effective post-exposure prevention of poison ivy dermatitis.

Int J Dermatol. 2000; 39: 515-518Davila A. Laurora M. Fulton J. Jacoby J.L. Heller M.B. Reed J. et al.

A new topical agent, Zanfel, ameliorates urushiol-induced Toxicodendron allergic contact dermatitis [abstract 364].

Ann Emerg Med. 2003; 42: S98

OTC product: Zanfel.

Pharm Today. 2009; 15: 19

Choosing topical corticosteroids.

Am Fam Physician. 2009; 79: 135-140

Failure of a tapering dose of oral methylprednisolone to treat reactions to poison ivy.

JAMA. 1991; 266: 1362

Poison ivy: how effective are available treatments?.

J Fam Pract. 2016; 65: 801-809

Treatment of severe poison ivy: a randomized, controlled trial of long versus short course oral prednisone.

J Clin Med Res. 2014; 6: 429-434